Every 10-Q that Vor Biopharma Inc. (VOR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VOR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VOR filings page.
Vor Biopharma Inc. reported a net loss of $62.8 million for the quarter ended June 30 2026, a sharp improvement from a $1.57 billion loss a year earlier that was driven by a large non‑cash warrant revaluation and an upfront license charge. For the first six months of 2026, net loss was $282.4 million.
Operating expenses declined to $47.9 million in the quarter, with research and development at $25.9 million versus $261.5 million a year ago, mainly reflecting the absence of the prior‑year $222.6 million telitacicept license expense and lease‑termination costs. General and administrative expenses rose to $21.9 million, driven by higher stock‑based compensation, commercial build‑out, and professional fees.
Cash, cash equivalents and marketable securities totaled $466.1 million at June 30 2026. Including $48.9 million of gross proceeds from July at‑the‑market stock sales, management expects funding to support operations into early 2029 while advancing global Phase 3 trials of telitacicept in generalized myasthenia gravis and Sjögren’s disease.
Vor Biopharma reports first-quarter 2026 results showing it remains a clinical-stage company investing heavily in autoimmune programs while holding a large cash balance. The company recorded a net loss of $219.6 million for the three months ended March 31, 2026, largely driven by a $188.4 million non‑cash loss from the change in fair value of warrant liabilities.
Operating expenses were $35.2 million, with research and development at $17.6 million as spending shifted from legacy oncology programs to new telitacicept trials in generalized myasthenia gravis and Sjögren’s disease. General and administrative costs rose to $17.6 million, mainly from higher stock‑based compensation and commercial planning.
Vor reported cash, cash equivalents and marketable securities of $491.5 million as of March 31, 2026 and expects this to fund operations into early 2029. The company also highlighted multiple equity financings and warrant structures, including liability‑classified 2025 warrants with a fair value of $638.5 million, as key elements of its capital structure.
Vor Biopharma Inc. filed its Q3 2025 10‑Q, highlighting a pivot to autoimmune diseases centered on telitacicept and significant non‑cash items that dominated results. The company reported a net loss of $812.7 million for the quarter and $2,418.8 million for the nine months, largely driven by a $790.5 million quarterly and $2,090.4 million year‑to‑date change in the fair value of liability‑classified warrants.
Operating expenses were $28.1 million in Q3, including $14.1 million for R&D and $14.0 million for G&A. Year‑to‑date, R&D includes a $222.6 million charge for the telitacicept license (cash $45.0 million plus a warrant initially valued at $177.4 million) and $29.7 million of restructuring costs tied to the wind‑down of prior programs and a lease termination.
Cash, cash equivalents and marketable securities were $170.5 million as of September 30, 2025. Subsequent financings added $49.8 million via an October at‑the‑market sale and approximately $93.7 million from a November underwritten offering, with an additional $14.1 million expected from the overallotment. Management projects liquidity to fund operations into the second quarter of 2027.
Vor Biopharma reported a dramatic net loss of $1.606 billion for the six months ended June 30, 2025, driven primarily by a $1.299 billion non-cash increase in the fair value of newly issued warrant liabilities. The company held $200.6 million of cash, cash equivalents and marketable securities at June 30, 2025, and raised $174.4 million of net proceeds from a June 2025 private placement of PIPE warrants, which management says alleviated prior substantial doubt about near-term liquidity.
The company in-licensed telitacicept from RemeGen, paying a $45.0 million upfront cash fee and issuing RemeGen warrants initially valued at $177.4 million, and recorded a $222.6 million research and development charge as part of that acquisition. Vor also implemented a Restructuring Plan in May 2025, reducing headcount by 154 employees (about 99%) and recording $30.7 million of restructuring costs, leaving a remaining severance liability of $11.5 million at June 30, 2025. Total assets were $205.4 million and stockholders' deficit was $(1,505.7) million at period end.